Article
Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy.
Respiratory medicine - 1 Oct 2023
Sansores R H, Ramírez-Venegas A, Montiel-Lopez F, Domínguez-Arellano S, Alva-Lopez L F, Falfán-Valencia R, Pérez-Rubio G, Olaya-López E, Zavaleta-Martínez E O, Aguilar-Medina S, Escobar-Alvarado J C, Poo J L, Matera M G, Cazzola M
Abstract excerpt
INTRODUCTION: One of the major concerns with post-acute sequelae of COVID-19 (PASC) is the development of pulmonary fibrosis, for which no approved pharmacological treatment exists. Therefore, the primary aim of this open-label study was to evaluate the safety and the potential clinical efficacy of a prolonged-release pirfenidone formulation (PR-PFD) in patients having PASC-pulmonary fibrosis. METHODS: Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.